content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                      ----------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): October 11, 2006
                                                           ----------------
  
                                 CYTOGEN CORPORATION
                ----------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
            Delaware                      000-14879                22-2322400
  -----------------------------   ------------------------     -------------------
  (State or Other Jurisdiction    (Commission File Number)      (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
   650 College Road East, CN 5308, Suite 3100, Princeton, NJ          08540
  -----------------------------------------------------------    -----------------
          (Address of Principal Executive Offices)                 (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  
  
  
  <PAGE>
  
  
  ITEM 1.01  ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
  
  
       On  October  11,  2006,  Cytogen  Corporation   ("Cytogen")  announced  the
  execution of a license agreement with InPharma AS ("InPharma")  granting Cytogen
  exclusive  rights for  CAPHOSOL(R)  in North America.  CAPHOSOL,  a topical oral
  agent, is a prescription  medical device  indicated in the U.S. as an adjunct to
  standard oral care in treating oral  mucositis  caused by radiation or high dose
  chemotherapy.   CAPHOSOL   is  also   indicated   for   dryness   of  the  mouth
  (hyposalivation) or dryness of the throat  (xerostomia)  regardless of the cause
  or whether the conditions are temporary or permanent.
  
       Under the terms of the agreement,  InPharma will receive upfront fees of $5
  million upon the closing of the transaction and an additional $1 million payment
  after six months.  In addition,  InPharma will receive royalties and sales-based
  milestone  payments.  The transaction  also provides  Cytogen with the option to
  acquire the rights to CAPHOSOL for the European and Asian markets.
  
       Attached hereto and  incorporated by reference  herein as Exhibit 99.1 is a
  copy of the related press release of Cytogen, dated October 11, 2006.
  
  ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS.
  
  (c) Exhibits.
  
        Exhibit No.       Description
        -----------       -----------
  
           99.1           Press Release of Cytogen dated October 11, 2006
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                          CYTOGEN CORPORATION
  
  
  
                                          By:/s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  Dated:   October 13, 2006
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
        Exhibit No.       Description
        -----------       -----------
  
           99.1           Press Release of Cytogen dated October 11, 2006
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k_101306.txt", "description": "FORM 8-K 101306", "secsgml_size_bytes": 4529}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "061144114"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                      ----------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): October 11, 2006
                                                           ----------------
  
                                 CYTOGEN CORPORATION
                ----------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
            Delaware                      000-14879                22-2322400
  -----------------------------   ------------------------     -------------------
  (State or Other Jurisdiction    (Commission File Number)      (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
   650 College Road East, CN 5308, Suite 3100, Princeton, NJ          08540
  -----------------------------------------------------------    -----------------
          (Address of Principal Executive Offices)                 (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  ITEM 1.01  ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
  
       On  October  11,  2006,  Cytogen  Corporation   ("Cytogen")  announced  the
  execution of a license agreement with InPharma AS ("InPharma")  granting Cytogen
  exclusive  rights for  CAPHOSOL(R)  in North America.  CAPHOSOL,  a topical oral
  agent, is a prescription  medical device  indicated in the U.S. as an adjunct to
  standard oral care in treating oral  mucositis  caused by radiation or high dose
  chemotherapy.   CAPHOSOL   is  also   indicated   for   dryness   of  the  mouth
  (hyposalivation) or dryness of the throat  (xerostomia)  regardless of the cause
  or whether the conditions are temporary or permanent.
  
       Under the terms of the agreement,  InPharma will receive upfront fees of $5
  million upon the closing of the transaction and an additional $1 million payment
  after six months.  In addition,  InPharma will receive royalties and sales-based
  milestone  payments.  The transaction  also provides  Cytogen with the option to
  acquire the rights to CAPHOSOL for the European and Asian markets.
  
       Attached hereto and  incorporated by reference  herein as Exhibit 99.1 is a
  copy of the related press release of Cytogen, dated October 11, 2006.
  
  ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS.
  
  (c) Exhibits.
  
        Exhibit No.       Description
        -----------       -----------
  
           99.1           Press Release of Cytogen dated October 11, 2006
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                          CYTOGEN CORPORATION
  
                                          By:/s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  Dated:   October 13, 2006
  EXHIBIT INDEX
  
        Exhibit No.       Description
        -----------       -----------
  
           99.1           Press Release of Cytogen dated October 11, 2006